Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar 8:2025:3517328.
doi: 10.1155/crom/3517328. eCollection 2025.

Immune Checkpoint Inhibitor-Mediated Aseptic Meningitis and Hypophysitis

Pavel Bleik  1 , Panisara Fangsaard  1 , Nataliya Yuklyaeva  1
Affiliations
Case Reports

Immune Checkpoint Inhibitor-Mediated Aseptic Meningitis and Hypophysitis

Pavel Bleik et al. Case Rep Oncol Med. .

Abstract

Immune checkpoint inhibitors have revolutionized cancer treatment, yet their use is associated with unique and sometimes unpredictable immune-related adverse events. We present a case of a 67-year-old female with renal cell cancer treated with ipilimumab and nivolumab who developed aseptic meningitis and hypophysitis. This case highlights the challenges in managing immune-related adverse events and underscores the need for vigilance in monitoring patients receiving ICIs.

Keywords: immunotherapy; ipilimumab; nivolumab; oncology; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Left renal mass (the blue arrow) measured 10 × 8 × 10 cm clinically correlates with malignancy.
Figure 2
Figure 2
Brain MRI done before the treatment was started. No evidence of metastatic disease. Hypophysis appears normal.
Figure 3
Figure 3
MRI done during the hospital admission. The blue arrow points to changes in the pituitary gland.
Figure 4
Figure 4
MRI done 4 weeks later shows no abnormalities.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Weber J. S., Kähler K. C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology . 2012;30(21):2691–2697. doi: 10.1200/JCO.2012.41.6750. - DOI - PubMed
    1. Thouvenin L., Olivier T., Banna G., Addeo A., Friedlaender A. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Therapeutic Advances in Drug Safety . 2021;12 doi: 10.1177/20420986211004745. - DOI - PMC - PubMed
    1. Hartmann A., Paparoupa M., Volkmer B. G., Rompel R., Wittig A., Schuppert F. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: four cases describing the clinical heterogeneity of central endocrine dysfunction. Journal of Oncology Pharmacy Practice . 2020;26(7):1774–1779. doi: 10.1177/1078155220910202. - DOI - PubMed
    1. Mohamed A., Zavoshi S., Mahmood R., Gidda H. The impact of granulocyte colony-stimulating factor administration in a neutropenic cancer patient with COVID-19-related acute respiratory distress syndrome. Cureus . 2023;15(2) doi: 10.7759/cureus.35399.e35399 - DOI - PMC - PubMed
    1. Wang C., Thudium K. B., Han M., et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunology Research . 2014;2(9):846–856. doi: 10.1158/2326-6066.CIR-14-0040. - DOI - PubMed

Publication types

LinkOut - more resources